Does switching between anti-CGRP mAbs reduce monthly headache days in patients with migraine who do not respond to initial mAb therapy?
Switching between anti-CGRP monoclonal antibodies is an effective strategy for migraine patients who fail initial mAb therapy, regardless of the specific mechanism of action.
Switching between anti-CGRP mAbs resulted in a reduction in MHDs, with no significant differences based on the mechanism of action. Factors such as the number of doses of the first mAb and the inter-treatment interval did not appear to predict a ≥50% reduction in MHDs at month 3. Our findings support the viability of switching as an effective treatment option for patients with migraine who do not respond to initial mAb therapy.
Jaimes et al. (Fri,) studied this question.